You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

Drugs

The drug library provides access to information on over 100 cancer drugs available for use in Canada.

Displaying Drugs List

9 Items
Other Name(s): Xtandi® (Astellas)
Funding:
Exceptional Access Program
  • enzalutamide - For the treatment of metastatic castrate-resistant prostate cancer (mCRPC), according to specific criteria
Nov 2016
Other Name(s): Pharmorubicin PFS® (multiple brands available)
Funding:
New Drug Funding Program
  • Epirubicin - Adjuvant Treatment for Breast Cancer
  • Epirubicin - Neoadjuvant Treatment for Non-Metastatic Breast Cancer
Aug 2016
Other Name(s): Eprex ® (Janssen)
Funding:
Exceptional Access Program
  • epoetin - Anemia in palliative cancer patients, with specific criteria
  • epoetin - Anemia secondary to MDS, with specific criteria
ODB Limited Use
  • epoetin - Patients with cancer diagnosis and receiving chemotherapy, with specific criteria
Mar 2013
Other Name(s): Halaven® (Eisai)
Funding:
New Drug Funding Program
  • Eribulin - Metastatic or Incurable Locally Advanced - Breast Cancer
Updated
Jan 2018
Other Name(s): Tarceva® (Hoffmann-LaRoche)
Funding:
Exceptional Access Program
  • erlotinib - Incurable progressive NSCLC, with specific criteria
May 2017
Other Name(s): Emcyt® (Pfizer)
Funding:
ODB - General Benefit
  • estramustine
Mar 2013
Other Name(s): Vepesid® (multiple brands available)
Funding:
ODB - General Benefit
  • etoposide - oral capsules
Nov 2017
Other Name(s): Afinitor® (Novartis)
Funding:
Exceptional Access Program
  • everolimus - In combination with exemestane, for the treatment of hormone-receptor positive, HER2 negative advanced breast cancer, in postmenopausal women with ECOG performance status less than or equal to 2 after recurrence or progression following a non-steroidal aromatase inhibitor (NSAI)
  • everolimus - Metastatic renal cell carcinoma, with specific criteria
  • everolimus - For the treatment of unresectable, locally advanced or metastatic, well-differentiated non-functional neuroendocrine tumours (NETs) of GI or lung origin, according to clinical criteria
Dec 2017
Other Name(s): Aromasin® (multiple brands available)
Funding:
ODB Limited Use
  • exemestane - In combination with everolimus, for the treatment of hormone-receptor positive HER2 negative advanced breast cancer, in postmenopausal women with ECOG performance status less than or equal to 2 after recurrence or progression following a non-steroidal aromatase inhibitor (NSAI)
  • exemestane - Hormonal treatment of metastatic breast cancer in hormone receptor positive postmenopausal women who have disease progression following tamoxifen therapy
  • exemestane - Sequential treatment of postmenopausal women with estrogen receptor-positive early breast cancer who have received 2-3 years of initial adjuvant tamoxifen therapy
May 2014